Status:
COMPLETED
Subject Insights to Understand the Hand Osteoarthritis (HOA)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Osteoarthritis
Eligibility:
All Genders
40-80 years
Brief Summary
Osteoarthritis (OA) is a degenerative joint disease which causes joints to become painful and stiff. HOA is the second most common form of OA and is characterized by stiffness, joint pain and inflamma...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Erosive Hand OA
- Subject is a male or female between 40-80 years of age (inclusive) at the time of signing the informed consent form.
- Subject meets the American College of Rheumatology (ACR) classification of osteoarthritis: Hand pain, aching, or stiffness and 3 or 4 of the following features: Hard tissue enlargement of 2 or more of 10 selected joints, Hard tissue enlargement of 2 or more distal interphalangeal (DIP) joints, Fewer than 3 swollen metatarsophalangeal (MCP) joints or Deformity of at least 1of 10 selected joints where The 10 selected joints are the second and third DIP, the second and third proximal interphalangeal (PIP), and the first carpometacarpal joints of both hands.
- Subject has erosive disease on at least 1 PIP or 1DIP joint as demonstrated by imaging evidence \[can include X-ray, ultrasound or magnetic resonance imaging (MRI) evidence\].
- Subject has active disease in at least one hand, with at least two soft tissue swollen and tender PIP and/or DIP joints in the affected hand by clinical examination within the past 3 months. If only one hand is affected by HOA and meets the inclusion criteria, the affected hand should be documented at screening and used for all assessments. In cases where both hands are affected by HOA and both meet the inclusion criteria, then the dominant hand should be documented at screening and used for all assessments.
- Subject's self-reported average hand-pain intensity over the past 7 days must be at least '4' on a 0-10 Numerical Rating Scale (NRS).
- Subject must have negative titer rheumatoid factor (RF) and anti- Cyclic Citrullinated Peptide (CCP) antibody.
- Subject must have a personally signed and dated written informed consent form prior to admission to the study.
- Subject must be verbally fluent and literate in English.
- Subject must be able to attend and participate in two 45 minute telephone or video call (Skype or Facetime) interviews (either on the same day or separate days).
- Inclusion Criteria for Non-Erosive Hand OA
- Subject is a male or female between 40-80 years of age (inclusive) at the time of signing the informed consent form
- Subject meets the American College of Rheumatology (ACR) classification of osteoarthritis: Hand pain, aching, or stiffness and 3 or 4 of the following features: Hard tissue enlargement of 2 or more of 10 selected joints, Hard tissue enlargement of 2 or more distal interphalangeal (DIP) joints, Fewer than 3 swollen metacarpophalangeal (MCP) joints, Deformity of at least 1 of 10 selected joints where the 10 selected joints are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands.
- Subject has at least 1 finger joint (DIP or PIP) with K-L ≥ 2 \[by x-ray in last 12m\]. Participant's self-reported average hand-pain intensity over the past 7 days must be moderate to severe (≥4 on a 0-10 Numeric Rating Scale \[NRS\] or ≥40mm on a 0-100mm Visual Analog Scale \[VAS\]). If only one hand is affected by hand osteoarthritis (HOA) and meets the inclusion criteria, the affected hand should be documented at screening and used for all assessments. In cases where both hands are affected by HOA and both meet the inclusion criteria, then the dominant hand should be documented at screening and used for all assessments.
- Subject is unwilling or unable to take non-opiate analgesics, or is inadequately controlled by non-opiate analgesics (non-opiate analgesics include Tramadol)
- Subject must have negative titer rheumatoid factor (RF) and anti-CCP antibody
- Subject must have a personally signed and dated written informed consent form prior to admission to the study
- Subject must be verbally fluent and literate in English
- Subject must be able to attend and participate in two 45 minute telephone or video call (Skype or Facetime) interviews (either on the same day or separate days)
- Inclusion criteria for subjects taking part in real-time data capture:
- Subject owns/or has access to either a smartphone \[iPhone Operating System (iOS) or android\] or tablet which has video, audio/microphone and photographic capabilities and access to either the Apple app store or Google play store to download the app.
- Subject is willing and able to take part in the real time data application task and respond to a series of questions/tasks fielded via the application over the course of seven days.\]
- Subject would feel comfortable recording short videos of themselves and providing audio commentary in response to app questions/tasks.
Exclusion
- Exclusion Criteria for Erosive Hand OA
- Subject has history of any clinically significant inflammatory disease other than inflammatory osteoarthritis, especially, but not limited to, rheumatoid arthritis or spondylarthropathies.
- Subject has a diagnosis of rheumatoid arthritis, fibromyalgia, gout, calcium pyrophosphate deposition disease (CPPD), pseudogout, hemochromatosis or other inflammatory rheumatological or autoimmune disorders.
- Subject has had a clinical suspicion of, or previous investigation for CPPD or pseudogout, or history of chondrocalcinosis.
- Subject has any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand osteoarthritis joint(s).
- Subject has great difficulty hearing, reading or speaking.
- Subject has an uncontrolled psychiatric condition (example, schizophrenia,bipolar disorder) or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study or likely to have difficulty participating in two 45 minute interviews.
- Subject has severe physical, neurological or cognitive deficits that might prohibit the ability to participate in an interview about the experience of their hand osteoarthritis and completion of a questionnaire.
- Subject is currently or has previously been enrolled in a clinical trial for OA in the past 6 months.
- Exclusion Criteria for Non-Erosive Hand OA
- Subject has erosive disease on any proximal interphalangeal (PIP) or distal interphalangeal (DIP) joints as evidenced via X-ray, MRI or ultrasound
- Subject has history of any clinically significant inflammatory disease other than inflammatory osteoarthritis, especially, but not limited to, rheumatoid arthritis or spondylarthropathies
- Subject has a diagnosis of rheumatoid arthritis, fibromyalgia, gout, calcium pyrophosphate deposition disease (CPPD), pseudogout, hemochromatosis or other inflammatory rheumatological or autoimmune disorders
- Subject has had a clinical suspicion of, or previous investigation for CPPD or pseudogout, or history of chondrocalcinosis
- Subject has any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand osteoarthritis joint(s)
- Subject has great difficulty hearing, reading or speaking
- Subject has an uncontrolled psychiatric condition (e.g., schizophrenia, bipolar disorder) or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study or likely to have difficulty participating in two 45 minute interviews
- Subject has severe physical, neurological or cognitive deficits that might prohibit the ability to participate in an interview about the experience of their hand osteoarthritis and completion of a questionnaire
- Subject is currently or has previously been enrolled in a clinical trial for hand OA in the past six months
Key Trial Info
Start Date :
July 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03271203
Start Date
July 3 2017
End Date
October 30 2017
Last Update
October 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Bollington, Cheshire, United Kingdom, SK10 5JB